Alumis logo

Alumis

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

249 employees · est. 2021 · South San Francisco, United...

VS
RetinAI logo

RetinAI

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.

43 employees · est. 2017 · Bern, Switzerland

RetinAI is the older company (2021 vs 2017); Alumis is the larger of the two.

Side-by-Side Comparison

Alumis RetinAI
Founded
2021 2017 older
Headquarters
South San Francisco, United States Bern, Switzerland
Employees
249 larger 43
Industry
Biotechnology, Health Care, Life Sciences AI, Computing, Health Care
Funding Stage
Series C Series B
Total Funding
$529.00M $15.14M
Funding Rounds
3 8
Services
Development of targeted therapies, Clinical trial management, Proprietary data analytics for precision medicine, Patient resources and expanded access policy Not tracked yet
Target Customers
Patients with immune-mediated diseases, Healthcare providers, Medical researchers, Investors in biotech and pharmaceutical sectors Not tracked yet
Taxonomy
Immune-mediated Diseases, Precision Medicine, Targeted Therapies, Drug Development, Autoimmune Diseases, Immunology, Pharmaceuticals, Integrated Therapy Development, Immunosuppression Alternatives, Patient-centric Solutions, Disease-specific Drug Targeting, Therapeutic Innovation, Healthcare Analytics Medical Image Analysis, Med-tech, Ophthalmology, Optical Coherence Tomography, Fundus Image Photography, Retinal Angiography, Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Multiple Sclerosis, Alzheimer, Parkinson, Digital Health
Website
alumis.com retinai.com
Alumis logo

About Alumis

Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimiz...

RetinAI logo

About RetinAI

RetinAI is a Swiss & US-based software company focused on improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials, and enabling the research needed to elevate the quality of care on patients with eye diseases. The company's slogan "Im...

We will tell you when either one moves

BounceWatch watches Alumis and RetinAI for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Alumis and RetinAI — by email.

Frequently Asked Questions

Alumis — Transforming the lives of patients living with immune-mediated diseases using a precision approach.. RetinAI — Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Alumis has raised $529.00M while RetinAI has raised $15.14M.
Alumis and RetinAI operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Alumis with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Alumis on 9 Jun 2026, and RetinAI on 24 Feb 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy